TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

Transcenta, biologics, antibody

TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company

contact 中文
Press Release

Transcenta and 908 Devices Expand Joint Innovation Partnership

02 Apr, 2020

Transcenta, a global biotherapeutics company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacturing, today announced an expansion of their joint innovation partnership with 908 Devices, a pioneer of analytical devices for chemical and biomolecular analysis.

Back in mid-2018, Transcenta's subsidiary HJB entered into a partnership to bring in 908 Devices' ZipChip system that has been a critical part of the Center's analytical toolset - streamlining internal processes and enabling rapid measurement of Critical Quality Attributes (CQAs), native proteins, and small molecules. Transcenta will now deploy 908 Devices' Rebel system, a first of its kind analyzer for at-line analysis on key components in cell culture media, to accelerate our process development cycles.

"We value our partnership with 908 Devices and their ZipChip has become our workhorse for large molecule and media component analyses.  When integrated with our mass spec, it provided the speed and higher resolution needed to help us accelerate our CMC development.  Now with Rebel in our tool kit, with its ultra-fast analysis of amino acids and vitamins, it will allow us to make real-time decisions to further accelerate our media development and optimization efforts and intensify our cell culture processes and push our continuous perfusion process beyond the 4 g/L-day that was recently announced and advance our Integrated Continuous Bioprocessing (ICB) platform." - said Dr. Christopher Hwang, CTO of Transcenta.

"Transcenta leads the way in deploying state-of-the-art tools in their biologics discovery and development workflows. It's exciting to take our collaboration with Transcenta into this next phase, and to see how ZipChip and Rebel can work in tandem to help drive that innovation," said Dr. Kevin J. Knopp, CEO and Co-Founder of 908 Devices.


About 908 Devices

We make point-of-need-devices ranging from rugged, handheld chemical detection tools to compact, tiny footprint analyzers and fast separation devices. These uncomplicated purpose-built devices provide users with the power to redefine their workflows by getting actionable answers at the point of need. Our devices are being used for critical applications across the globe in the life sciences and field forensic markets.  908 Devices is headquartered in the heart of Boston, where we research, design and manufacture innovative products based on high-pressure mass spectrometryTM (HPMS) and microfluidic separation technology. For more information, visit 908devices.com.